{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:06:00Z","timestamp":1789639560543,"version":"4.0.0"},"reference-count":10,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2026-0271_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize postpartum maternal morbidity in women with sickle cell disease (SCD) and explore whether antepartum disease burden, transfusion exposure, and peripartum clinical factors were associated with postpartum maternal and breastfeeding outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2026-0271_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 37 deliveries in patients with confirmed SCD at a large urban academic center (2015\u20132025). Maternal, neonatal, transfusion, and breastfeeding outcomes were abstracted from the electronic medical record.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2026-0271_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-seven deliveries met inclusion criteria. The predominant genotype was HbSS (24\/37, 64.9\u202f%), followed by HbSC (7\/37), HbS\u03b2\n                      <jats:sup>0<\/jats:sup>\n                      -thalassemia (3\/37), HbS\u03b2\n                      <jats:sup>+<\/jats:sup>\n                      -thalassemia (2\/37), and HbS\/HPFH (1\/37). More than one-third of deliveries (13\/37, 35.1\u202f%) required transfusion within the first postpartum week. Postpartum hemorrhage\u00a0\u22651,000\u202fmL occurred in 5 of 37 deliveries (13.5\u202f%), and 5 of 36 (13.9\u202f%) required readmission within 6\u202fweeks postpartum, most commonly for vaso-occlusive crisis. NICU admission occurred in 14 of 37 neonates (37.8\u202f%). Breastfeeding intention was high (32\/33, 97\u202f%); persistence declined to 23 of 33 (69.7\u202f%) at 6\u202fweeks and\u00a012 of 34 (35.3\u202f%) at approximately 6\u202fmonths. Exploratory analyses suggested lower breastfeeding persistence among deliveries complicated by NICU admission and among those with greater antepartum clinical burden, including pregnancy transfusion, lower admission hemoglobin, and hospitalization during pregnancy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2026-0271_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The postpartum period in women with SCD is characterized by persistent hematologic morbidity, ongoing transfusion requirements, and declining breastfeeding persistence. Greater antepartum disease burden and neonatal complications may identify pregnancies at higher risk for adverse postpartum outcomes, supporting integrated hematology-obstetric care extending into the postpartum period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2026-0271","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:55:44Z","timestamp":1789638944000},"source":"Crossref","is-referenced-by-count":0,"title":["Postpartum outcomes in sickle cell disease: transfusion exposure, maternal morbidity, and breastfeeding persistence"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9027-1514","authenticated-orcid":false,"given":"Nawras","family":"Zayat","sequence":"first","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology and Women\u2019s Health, Montefiore Medical Center , Albert Einstein College of Medicine , Bronx , NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Bertuzzi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Montefiore Medical Center , Albert Einstein College of Medicine , Bronx , NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Eckman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center , Albert Einstein College of Medicine , Bronx , NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny","family":"Billett","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Montefiore Medical Center , Albert Einstein College of Medicine , Bronx , NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091709553970464_j_jpm-2026-0271_ref_001","doi-asserted-by":"crossref","unstructured":"James, AH, Strouse, JJ. How I treat sickle cell disease in pregnancy. Blood 2024;143:769\u201376. https:\/\/doi.org\/10.1182\/blood.2023020728.","DOI":"10.1182\/blood.2023020728"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_002","doi-asserted-by":"crossref","unstructured":"Kavanagh, PL, Fasipe, TA, Wun, T. Sickle cell disease: a review. JAMA 2022;328:57\u201368. https:\/\/doi.org\/10.1001\/jama.2022.10233.","DOI":"10.1001\/jama.2022.10233"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_003","doi-asserted-by":"crossref","unstructured":"Oteng-Ntim, E, Meeks, D, Seed, PT, Webster, L, Howard, J, Doyle, P, et al.. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015;125:3316\u201325. https:\/\/doi.org\/10.1182\/blood-2014-11-607317.","DOI":"10.1182\/blood-2014-11-607317"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_004","doi-asserted-by":"crossref","unstructured":"Boafor, TK, Olayemi, E, Galadanci, N, Hayfron-Benjamin, C, Dei-Adomakoh, Y, Segbefia, C, et al.. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016;123:691\u20138. https:\/\/doi.org\/10.1111\/1471-0528.13786.","DOI":"10.1111\/1471-0528.13786"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_005","doi-asserted-by":"crossref","unstructured":"Smith-Whitley, K. Complications in pregnant women with sickle cell disease. Hematol Am Soc Hematol Educ Program 2019;2019:359\u201366. https:\/\/doi.org\/10.1182\/hematology.2019000039.","DOI":"10.1182\/hematology.2019000039"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_006","doi-asserted-by":"crossref","unstructured":"Grande, J, Liu, J, Nemerofsky, S. Exclusive breastfeeding in the Bronx: successes and shortcomings. Am J Perinatol 2024;41:05. https:\/\/doi.org\/10.1055\/a-2129-8773.","DOI":"10.1055\/a-2129-8773"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_007","doi-asserted-by":"crossref","unstructured":"Chou, ST, Alsawas, M, Fasano, RM, Field, JJ, Hendrickson, JE, Howard, J, et al.. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020;4:327\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2019001143.","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_008","doi-asserted-by":"crossref","unstructured":"Loh, J, Kuo, KHM, Georgescu, I, Wang, S, Huszti, E, Shehata, N, et al.. Risk factors for immediate postpartum sickle cell disease-specific maternal morbidity. Br J Haematol 2025;207:225\u201334. https:\/\/doi.org\/10.1111\/bjh.20178.","DOI":"10.1111\/bjh.20178"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_009","doi-asserted-by":"crossref","unstructured":"Poliektov, NE, Vuncannon, DM, Ha, TK, Lindsay, MK, Chandrasekaran, S. The association between sickle cell disease and postpartum severe maternal morbidity. Am J Perinatol 2024;41:2144\u201351. https:\/\/doi.org\/10.1055\/s-0044-1786174.","DOI":"10.1055\/s-0044-1786174"},{"key":"2026091709553970464_j_jpm-2026-0271_ref_010","doi-asserted-by":"crossref","unstructured":"Diaz, LE, Yee, LM, Feinglass, J. Rates of breastfeeding initiation and duration in the United\u00a0States: data insights from the 2016\u20132019 pregnancy risk assessment monitoring system. Front Public Health 2023;11:1256432. https:\/\/doi.org\/10.3389\/fpubh.2023.1256432.","DOI":"10.3389\/fpubh.2023.1256432"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2026-0271\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2026-0271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:55:50Z","timestamp":1789638950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2026-0271\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":10,"alternative-id":["10.1515\/jpm-2026-0271"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2026-0271","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}